Disease Detection International Inc

Disease Detection International Inc. said Tuesday it had agreed to let Bio-Diagnostica Inc. of Miami distribute an AIDS test in Venezuela, Chile and Argentina. Disease Detection, based in Irvine, said the agreement may be worth as much as $8.7 million in sales to the company, which makes the SeroCard HIV-1 blood test.

Blood Test Maker Agrees: Disease Detection International Inc. said Tuesday it had agreed to let Bio-Diagnostica Inc. of Miami distribute an AIDS test in Venezuela, Chile and Argentina. Disease Detection, based in Irvine, said the agreement may be worth as much as $8.7 million in sales to the company, which makes the SeroCard HIV-1 blood test.

Disease Detection International Inc. said Monday that its Brazilian joint venture has won an order from the large state of Sao Paulo for as much as $4 million worth of the company's SeroCard HIV-1 AIDS tests. Sao Paulo will use the 1.2 million tests in a broad program for low-income people. The state has a population of 30 million and is expected to order more tests through next year, Disease Detection said.

Disease Detection International Inc. in Irvine said it has received $2.5 million from investors who bought shares of DDI stock by redeeming stock warrants. President H. Thad Morris said 98% of the company's outstanding warrants have been redeemed. Warrants are certificates that give holders the option to buy stock at a stated price. Morris said his company, which makes test kits to measure several diseases, plans to invest the proceeds from the stock sales in certificates of deposit and other short-term notes.

Disease Detection International Inc., an Irvine manufacturer of medical diagnostic test kits for hospitals and doctors offices, said Monday that its shareholders have approved a reverse stock plan. The action will reduce the publicly traded shares in the company while increasing the amount of new stock the company may sell in the future.

Disease Detection International Inc. said Monday that an Irish firm that is the largest single shareholder of the biomedical company wants to acquire it outright. Disease Detection, which makes products that detect sexually transmitted and other infectious diseases, would not reveal details of the proposal by Trinity Biotech PLC in Dublin other than that it would involve a stock swap.

Blood Test Maker Agrees: Disease Detection International Inc. said Tuesday it had agreed to let Bio-Diagnostica Inc. of Miami distribute an AIDS test in Venezuela, Chile and Argentina. Disease Detection, based in Irvine, said the agreement may be worth as much as $8.7 million in sales to the company, which makes the SeroCard HIV-1 blood test.

Disease Detection International Inc. said Tuesday it had agreed to let Bio-Diagnostica Inc. of Miami distribute an AIDS test in Venezuela, Chile and Argentina. Disease Detection, based in Irvine, said the agreement may be worth as much as $8.7 million in sales to the company, which makes the SeroCard HIV-1 blood test.

Disease Detection International Inc. said Monday that its Brazilian joint venture has won an order from the large state of Sao Paulo for as much as $4 million worth of the company's SeroCard HIV-1 AIDS tests. Sao Paulo will use the 1.2 million tests in a broad program for low-income people. The state has a population of 30 million and is expected to order more tests through next year, Disease Detection said.

Disease Detection International Inc., a maker of pregnancy and AIDS testing kits, said Monday that it has sold $3 million worth of convertible preferred stock in a private placement--which should help get the company's common stock listed on the NASDAQ market for small corporations. The Irvine concern said it will ask owners of the common stock to approve a 1-for-10 reverse split at the annual meeting in July. That means the 10.

Disease Detection International Inc. said Monday that an Irish firm that is the largest single shareholder of the biomedical company wants to acquire it outright. Disease Detection, which makes products that detect sexually transmitted and other infectious diseases, would not reveal details of the proposal by Trinity Biotech PLC in Dublin other than that it would involve a stock swap.

The developer of a seven-minute AIDS test and its former parent company have traded temporary restraining orders over the ownership of technology. Editek Inc. in Burlington, N.C., and Disease Detection International Inc. in Irvine are arguing over a licensing agreement they made in 1985, when Editek formed Disease Detection. The subsidiary was spun off in 1988. Over the years, both companies have continued to develop biological tests.

Disease Detection International Inc. of Irvine said Tuesday that it will begin clinical trials of a seven-minute AIDS test under U.S. Food and Drug Administration regulations. Schiff & Co.--a consultant in West Caldwell, N.J., that specializes in pharmaceutical and diagnostic regulations--will conduct the clinical studies and FDA submissions of the device, called SeroCard(R) HIV-1. Testing will require three to five months.